logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Andreas Johne

merck kga a
H指数:27
被引数:6,585

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION

特波替尼在MET外显子14跳跃的亚洲晚期NSCLC患者中的疗效和安全性

BRITISH JOURNAL OF CANCER
IF6.8
2024-04-040
OA
Kato, Terufumi; Yang, James Chih-Hsin; Ahn, Myung-Ju; Sakai, Hiroshi; Morise, Masahiro; Chen, Yuh-Min; Han, Ji-Youn; Yang, Jin-Ji; Zhao, Jun; Hsia, Te-Chun; Berghoff, Karin; Bruns, Rolf; Vioix, Helene; Lang, Simone; Johne, Andreas; Le, Xiuning; Paik, Paul K.
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
CELL REPORTS MEDICINE
IF10.6
2023-11-019
OAAI
Le, Xiuning; Paz-Ares, Luis G.; Van Meerbeeck, Jan; Viteri, Santiago; Galvez, Carlos Cabrera; Smit, Egbert F.; Garassino, Marina; Veillon, Remi; Baz, David Vicente; Pradera, Jose Fuentes; Sereno, Maria; Kozuki, Toshiyuki; Kim, Young-Chul; Yoo, Seung Soo; Han, Ji-Youn; Kang, Jin-Hyoung; Son, Choon-Hee; Choi, Yoon Ji; Stroh, Christopher; Juraeva, Dilafruz; Vioix, Helene; Bruns, Rolf; Otto, Gordon; Johne, Andreas; Paik, Paul K.
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

特波替尼联合吉非替尼与化疗治疗因MET扩增而产生EGFR抑制剂耐药的EGFR突变型NSCLC的随机试验: 洞察力最终分析

CLINICAL CANCER RESEARCH
IF10.2
2023-03-2716
OAAI
Liam, Chong Kin; Ahmad, Azura Rozila; Hsia, Te-Chun; Zhou, Jianying; Kim, Dong-Wan; Soo, Ross Andrew; Cheng, Ying; Lu, Shun; Shin, Sang Won; Yang, James Chih-Hsin; Zhang, Yiping; Zhao, Jun; Berghoff, Karin; Bruns, Rolf; Johne, Andreas; Wu, Yi-Long
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Tepotinib联合吉非替尼治疗EGFR突变型非小细胞肺癌伴MET过表达或MET扩增并对先前EGFR抑制剂获得性耐药的患者 (INSIGHT研究): 一项开放标签、1b/2期、多中心、随机试验

LANCET RESPIRATORY MEDICINE
IF32.8
2020-11-01193
PREAI
Wu, Yi-Long; Cheng, Ying; Zhou, Jianying; Lu, Shun; Zhang, Yiping; Zhao, Jun; Kim, Dong-Wan; Soo, Ross Andrew; Kim, Sang-We; Pan, Hongming; Chen, Yuh-Min; Chian, Chih-Feng; Liu, Xiaoqing; Tan, Daniel Shao Weng; Bruns, Rolf; Straub, Josef; Johne, Andreas; Scheele, Jurgen; Park, Keunchil; Yang, James Chih-Hsin
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Tepotinib在MET外显子14跳跃突变的非小细胞肺癌中的应用

NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2020-09-03579
OAAI
Paik, Paul K.; Felip, Enriqueta; Veillon, Remi; Sakai, Hiroshi; Cortot, Alexis B.; Garassino, Marina C.; Mazieres, Julien; Viteri, Santiago; Senellart, Helene; Van Meerbeeck, Jan; Raskin, Jo; Reinmuth, Niels; Conte, Pierfranco; Kowalski, Dariusz; Cho, Byoung Chul; Patel, Jyoti D.; Horn, Leora; Griesinger, Frank; Han, Ji-Youn; Kim, Young-Chul; Chang, Gee-Chen; Tsai, Chen-Liang; Yang, James C. -H.; Chen, Yuh-Min; Smit, Egbert F.; van der Wekken, Anthonie J.; Kato, Terufumi; Juraeva, Dilafruz; Stroh, Christopher; Bruns, Rolf; Straub, Josef; Johne, Andreas; Scheele, Juergen; Heymach, John V.; Le, Xiuning

研究方向

暂未获取到该数据
R
Rolf Bruns
H 指数:14论文数:182被引数:1,903
P
Paul K. Paik
H 指数:45论文数:453被引数:1.4万
I
Ivar Roots
H 指数:76论文数:395被引数:2.0万
J
James Chih‐Hsin Yang
H 指数:141论文数:1,223被引数:10.9万
C
Christopher Stroh
H 指数:32论文数:133被引数:1.1万
M
Manfred Klevesath
H 指数:11论文数:41被引数:953
I
Ingrid Mai
H 指数:24论文数:66被引数:3,127
X
Xiuning Le
H 指数:50论文数:470被引数:1.1万
K
Klemens Budde
H 指数:89论文数:979被引数:3.3万
G
Gerald S. Falchook
H 指数:68论文数:810被引数:2.6万